Menstrual and reproductive factors in women, genetic variation in CYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort (pages 2164–2175)
Eric J. Duell, Noémie Travier, Leila Lujan-Barroso, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Rosario Tumino, Giovanna Masala, Vittorio Krogh, Salvatore Panico, Fulvio Ricceri, Maria Luisa Redondo, Miren Dorronsoro, Esther Molina-Montes, José M. Huerta, Aurelio Barricarte, Kay-Tee Khaw, Nick J. Wareham, Naomi E. Allen, Ruth Travis, Peter D. Siersema, Petra H.M. Peeters, Antonia Trichopoulou, Eirini Fragogeorgi, Eleni Oikonomou, Heiner Boeing, Madlen Schuetze, Federico Canzian, Annekatrin Lukanova, Anne Tjønneland, Nina Roswall, Kim Overvad, Elisabete Weiderpass, Inger Torhild Gram, Eiliv Lund, Björn Lindkvist, Dorthe Johansen, Weimin Ye, Malin Sund, Veronika Fedirko, Mazda Jenab, Dominique S. Michaud, Elio Riboli and H. Bas Bueno-de-Mesquita
Version of Record online: 30 OCT 2012 | DOI: 10.1002/ijc.27875
Because the incidence of pancreatic cancer is 30-50% higher in men than women, researchers have wondered whether exposure to estrogen might offer a protective effect. The answer thus far has been unclear, however. In this study, the authors examined menstrual and reproductive factors in women, as well as exogenous hormone use. They also examined variants of the CYP17A1 gene in both women and men, as this gene is essential for sex-steroid metabolism. Only early age of menarche showed any association with pancreatic cancer risk.